ROOT: 160% | ‘Car-Insurance Firm Root Gets Takeover Bid; Root Was Offered $19.34 A Share, Hasn’t Managed To Negotiate A Deal’
ROIV: 15% | Roivant Reports Chronic Period Data for RVT-3101 from the TUSCANY-2 Phase 2b Study in Ulcerative Colitis, Demonstrating Improved Efficacy from the Induction to Chronic Period
ASLN: 29% | ASLAN Pharmaceuticals Enters Into a Strategic Licensing Deal With Zenyaku Kogyo for the Development and Commercialization of Eblasakimab in Japan
